Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Yen Stabilizes After Intervention Slide as Australian Dollar Hits Eight-Week High 
US Dollar Near Two-Month Low as Markets Await Inflation Data 
Gold Price Hits Two-Month High as Investors Await US Inflation Data 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Iran-Oman Near Strait of Hormuz Deal as Shipping Tensions Persist 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
European Stocks Flat as Oil Prices Rise, US CPI in Focus 
Asian Stocks Rise as Weak US Jobs Data Eases Fed Rate Hike Fears 
Singapore Raises 2026 GDP Growth Forecast to 4.5%-5.5% as AI Boom Fuels Economy 
Pfizer inc., an American pharmaceutical and biotechnology firm headquartered in Manhattan, New York City, has agreed to buy Global Blood Therapeutics biotech company for $5.4 billion. The drugmaker will be paying $68.50 a share for the acquisition.
According to Reuters, Pfizer will purchase the blood disorder medicine producer as it would like to bolster its drug lineup to counter or fight a possible slowdown in the demand for COVID medicines and other products since the cases are starting to fall.
Pfizer was one of the drugmakers that earned the most at the height of the COVID-19 pandemic since it supplied the vaccines around the world. With most people worldwide now fully vaccinated, the company is now looking for acquisitions that will bring in profits annually
Pfizer confirmed on Monday, Aug. 8, that it will be paying $68.50 per share to buy Global Blood Therapeutics. This amount is equivalent to a premium of around 7.3% to the stock's closing price last Friday.
Following the announcement of the deal with Pfizer, the shares of Global Blood reportedly soared by 4.5%. The company is known for its blood disorder drug called Oxbryta, which was first approved in 2019.
It is used for the treatment of sickle cell disease in patients who are 12 years old or older. In December 2021, it was also approved for the treatment of younger patients who are suffering from the said disease.
“Sickle cell disease is the most common inherited blood disorder, and it disproportionately affects people of African descent. We are excited to welcome GBT colleagues into Pfizer and to work together to transform the lives of patients, as we have long sought to address the needs of this underserved community,” Pfizer’s chairman and chief executive officer, Albert Bourla, said in a press release.
He added, “The deep market knowledge and scientific and clinical capabilities we have built over three decades in rare hematology will enable us to accelerate innovation for the sickle cell disease community and bring these treatments to patients as quickly as possible.”
